Cargando…
Co-targeting of IGF1R/mTOR pathway by miR-497 and miR-99a impairs hepatocellular carcinoma development
Persistent activation of IGF1R/mTOR signaling pathway plays crucial role in the development of hepatocellular carcinoma (HCC). Therefore, our goal was to elucidate microRNAs (miRNAs) targeting IGF1R/mTOR and the therapeutic potential of single or dual miRNA on HCC development. In this study, we foun...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564620/ https://www.ncbi.nlm.nih.gov/pubmed/28624790 http://dx.doi.org/10.18632/oncotarget.18207 |
_version_ | 1783258270698307584 |
---|---|
author | Cheng, Henghui Xue, Jin Yang, Shouhua Chen, Yaobin Wang, Yu Zhu, Yuanli Wang, Xiaoyan Kuang, Dong Ruan, Qiurong Duan, Yaqi Wang, Guoping |
author_facet | Cheng, Henghui Xue, Jin Yang, Shouhua Chen, Yaobin Wang, Yu Zhu, Yuanli Wang, Xiaoyan Kuang, Dong Ruan, Qiurong Duan, Yaqi Wang, Guoping |
author_sort | Cheng, Henghui |
collection | PubMed |
description | Persistent activation of IGF1R/mTOR signaling pathway plays crucial role in the development of hepatocellular carcinoma (HCC). Therefore, our goal was to elucidate microRNAs (miRNAs) targeting IGF1R/mTOR and the therapeutic potential of single or dual miRNA on HCC development. In this study, we found that miR-497 and miR-99a that target the 3′-UTR of both IGF1R and mTOR were down-regulated in HCC human tissues and cell lines. Functional assay revealed that ectopic expression of miR-497 or miR-99a in HCC cells resulted in a significant inhibition on tumor growth and invasiveness in vitro and tumor development in vivo via repressing the expression of IGF1R and mTOR. Such inhibitory effect on tumor growth is reversed by application of IGF1 ((IGF1R ligand) or MHY1485 (mTOR agonist) in vitro. Furthermore, we found that simultaneous over-expression of both miR-497 and miR-99a exhibited much stronger inhibitory effects on tumor growth than their individual effect, which is still correlated with significantly stronger repression of IGF1R and mTOR. Overall, our results suggest that miR-497 and miR-99a both function as tumor-suppressive miRNAs by suppressing IGF1R/mTOR signaling pathway. The synergistic actions of these two miRNAs partly correlated with IGF1R and mTOR levels, which may represent new strategies for the molecular treatment of HCC. |
format | Online Article Text |
id | pubmed-5564620 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-55646202017-08-23 Co-targeting of IGF1R/mTOR pathway by miR-497 and miR-99a impairs hepatocellular carcinoma development Cheng, Henghui Xue, Jin Yang, Shouhua Chen, Yaobin Wang, Yu Zhu, Yuanli Wang, Xiaoyan Kuang, Dong Ruan, Qiurong Duan, Yaqi Wang, Guoping Oncotarget Research Paper Persistent activation of IGF1R/mTOR signaling pathway plays crucial role in the development of hepatocellular carcinoma (HCC). Therefore, our goal was to elucidate microRNAs (miRNAs) targeting IGF1R/mTOR and the therapeutic potential of single or dual miRNA on HCC development. In this study, we found that miR-497 and miR-99a that target the 3′-UTR of both IGF1R and mTOR were down-regulated in HCC human tissues and cell lines. Functional assay revealed that ectopic expression of miR-497 or miR-99a in HCC cells resulted in a significant inhibition on tumor growth and invasiveness in vitro and tumor development in vivo via repressing the expression of IGF1R and mTOR. Such inhibitory effect on tumor growth is reversed by application of IGF1 ((IGF1R ligand) or MHY1485 (mTOR agonist) in vitro. Furthermore, we found that simultaneous over-expression of both miR-497 and miR-99a exhibited much stronger inhibitory effects on tumor growth than their individual effect, which is still correlated with significantly stronger repression of IGF1R and mTOR. Overall, our results suggest that miR-497 and miR-99a both function as tumor-suppressive miRNAs by suppressing IGF1R/mTOR signaling pathway. The synergistic actions of these two miRNAs partly correlated with IGF1R and mTOR levels, which may represent new strategies for the molecular treatment of HCC. Impact Journals LLC 2017-05-24 /pmc/articles/PMC5564620/ /pubmed/28624790 http://dx.doi.org/10.18632/oncotarget.18207 Text en Copyright: © 2017 Cheng et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (http://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Cheng, Henghui Xue, Jin Yang, Shouhua Chen, Yaobin Wang, Yu Zhu, Yuanli Wang, Xiaoyan Kuang, Dong Ruan, Qiurong Duan, Yaqi Wang, Guoping Co-targeting of IGF1R/mTOR pathway by miR-497 and miR-99a impairs hepatocellular carcinoma development |
title | Co-targeting of IGF1R/mTOR pathway by miR-497 and miR-99a impairs hepatocellular carcinoma development |
title_full | Co-targeting of IGF1R/mTOR pathway by miR-497 and miR-99a impairs hepatocellular carcinoma development |
title_fullStr | Co-targeting of IGF1R/mTOR pathway by miR-497 and miR-99a impairs hepatocellular carcinoma development |
title_full_unstemmed | Co-targeting of IGF1R/mTOR pathway by miR-497 and miR-99a impairs hepatocellular carcinoma development |
title_short | Co-targeting of IGF1R/mTOR pathway by miR-497 and miR-99a impairs hepatocellular carcinoma development |
title_sort | co-targeting of igf1r/mtor pathway by mir-497 and mir-99a impairs hepatocellular carcinoma development |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564620/ https://www.ncbi.nlm.nih.gov/pubmed/28624790 http://dx.doi.org/10.18632/oncotarget.18207 |
work_keys_str_mv | AT chenghenghui cotargetingofigf1rmtorpathwaybymir497andmir99aimpairshepatocellularcarcinomadevelopment AT xuejin cotargetingofigf1rmtorpathwaybymir497andmir99aimpairshepatocellularcarcinomadevelopment AT yangshouhua cotargetingofigf1rmtorpathwaybymir497andmir99aimpairshepatocellularcarcinomadevelopment AT chenyaobin cotargetingofigf1rmtorpathwaybymir497andmir99aimpairshepatocellularcarcinomadevelopment AT wangyu cotargetingofigf1rmtorpathwaybymir497andmir99aimpairshepatocellularcarcinomadevelopment AT zhuyuanli cotargetingofigf1rmtorpathwaybymir497andmir99aimpairshepatocellularcarcinomadevelopment AT wangxiaoyan cotargetingofigf1rmtorpathwaybymir497andmir99aimpairshepatocellularcarcinomadevelopment AT kuangdong cotargetingofigf1rmtorpathwaybymir497andmir99aimpairshepatocellularcarcinomadevelopment AT ruanqiurong cotargetingofigf1rmtorpathwaybymir497andmir99aimpairshepatocellularcarcinomadevelopment AT duanyaqi cotargetingofigf1rmtorpathwaybymir497andmir99aimpairshepatocellularcarcinomadevelopment AT wangguoping cotargetingofigf1rmtorpathwaybymir497andmir99aimpairshepatocellularcarcinomadevelopment |